FCMV
CMPX icon

Foresite Capital Management V’s Compass Therapeutics CMPX Stock Holding History

Foresite Capital Management V’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,246,977
Closed -$2.46M – 7
2023
Q3 		$2.46M Sell
1,246,977
-77,094
-6% -$191K 3.92% 6
2023
Q2 		$4.21M Sell
1,324,071
-2,156,652
-62% -$6.77M 3.08% 8
2023
Q1 		$11.4M Sell
3,480,723
-919,277
-21% -$3.61M 8.41% 5
2022
Q4 		$22.1M Hold
4,400,000
– – 17.19% 2
2022
Q3 		$10M Hold
4,400,000
– – 7.71% 7
2022
Q2 		$11.7M Hold
4,400,000
– – 8.15% 6
2022
Q1 		$6.03M Hold
4,400,000
– – 2.46% 11
2021
Q4 		$13.9M Buy
+4,400,000
New +$14.6M 3.43% 9

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Foresite Capital Management V's CMPX Position: Q4 2023 in Review

Foresite Capital Management V sold out of Compass Therapeutics (CMPX) in Q4 2023, closing a stake of 1,246,977 shares — an estimated $2.46M sold.

Foresite Capital Management V first reported a position in CMPX in Q4 2021 and held it in 8 quarters. The position peaked at $22.1M in Q4 2022. 77 funds tracked by Wall St. Rank hold CMPX as of Q4 2023.

  • Foresite Capital Management V reported no remaining Compass Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Foresite Capital Management V sold 1,246,977 Compass Therapeutics shares in Q4 2023, an estimated $2.46M.
  • Foresite Capital Management V first reported a position in Compass Therapeutics in Q4 2021 and held it in 8 quarters.
  • Foresite Capital Management V's Compass Therapeutics position peaked at $22.1M in Q4 2022.
  • 77 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2023.

Based on Foresite Capital Management V's 13F filing for Q4 2023, filed 13 Feb 2024.